Nedelkopoulou N, et al. - As a part of this research, experts attempted to appraise the efficacy of anti-tumor necrosis factor (anti-TNFα) therapy in the management of inflammatory bowel disease (IBD) and autoimmune liver disease (AILD). In patients with AILD, IBD could be aggressive, thereby warranting an escalation to anti-TNFα or switching to other biologics. It was deduced that anti-TNFα did not impair liver function and improved gut disease in maximum patients. This finding illustrated that anti-TNFα therapy could be beneficial and safe.